Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Breast Care (Basel, Switzerland)
|
January 15, 2021
Biomarkers in Her2- Positive Disease
Eva Valentina Klocker, Christoph Suppan
Drugs
|
January 17, 2025
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer
Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Arthritis Research & Therapy
|
January 14, 2025
Distribution of spinal damage in patients with axial spondyloarthritis as assessed by MRI: a prospective and blinded study
Andreas Haidmayer, Gabriel Adelsmayr, Christopher Spreizer, et al.
Breast Care (Basel, Switzerland)
|
January 27, 2022
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Christoph Suppan, Daniel Steiner, Eva Valentina Klocker, et al.
Molecular Oncology
|
December 2, 2020
Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR<sup>+</sup> breast cancer patients undergoing CDK4/6 treatment
Nadia Dandachi, Florian Posch, Ricarda Graf, et al.
Cancer Medicine
|
June 16, 2020
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients
Dominik Andreas Barth, Carina Brenner, Jakob Michael Riedl, et al.
Cancers
|
May 8, 2020
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients
Eva Valentina Klocker, Dominik Andreas Barth, Jakob Michael Riedl, et al.
Cancers
|
June 2, 2021
Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
Christoph Suppan, Florian Posch, Hannah Deborah Mueller, et al.
Molecular Oncology
|
June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
British Journal of Cancer
|
November 10, 2021
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients
Christoph Suppan, Ricarda Graf, Stephan Jahn, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Breast Care (Basel, Switzerland)
|
January 15, 2021
Biomarkers in Her2- Positive Disease
Eva Valentina Klocker, Christoph Suppan
Drugs
|
January 17, 2025
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer
Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Arthritis Research & Therapy
|
January 14, 2025
Distribution of spinal damage in patients with axial spondyloarthritis as assessed by MRI: a prospective and blinded study
Andreas Haidmayer, Gabriel Adelsmayr, Christopher Spreizer, et al.
Breast Care (Basel, Switzerland)
|
January 27, 2022
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Christoph Suppan, Daniel Steiner, Eva Valentina Klocker, et al.
Molecular Oncology
|
December 2, 2020
Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR<sup>+</sup> breast cancer patients undergoing CDK4/6 treatment
Nadia Dandachi, Florian Posch, Ricarda Graf, et al.
Cancer Medicine
|
June 16, 2020
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients
Dominik Andreas Barth, Carina Brenner, Jakob Michael Riedl, et al.
Cancers
|
May 8, 2020
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients
Eva Valentina Klocker, Dominik Andreas Barth, Jakob Michael Riedl, et al.
Cancers
|
June 2, 2021
Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
Christoph Suppan, Florian Posch, Hannah Deborah Mueller, et al.
Molecular Oncology
|
June 13, 2024
Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, et al.
British Journal of Cancer
|
November 10, 2021
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients
Christoph Suppan, Ricarda Graf, Stephan Jahn, et al.
Page
of 2